Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00855920 · ClinicalTrials.gov registry record · Phase 3
Study Utilizing Rilonacept in Gout Exacerbations
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
NCT00855920 is a Phase 3 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 225 participants.
The verdict
NCT00855920, a Phase 3 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
Study Summary
This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of Rilonacept plus Indomethacin in treating acute gout flares.
Interventions
- DRUG Indomethacin
- DRUG Rilonacept
- OTHER Placebo (for Indomethacin)
- OTHER Placebo (for Rilonacept)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00855920
The ClinicalTrials.gov registry entry for NCT00855920 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Indomethacin is the first listed.
NCT00855920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00855920 about?
NCT00855920 is a clinical study titled "Study Utilizing Rilonacept in Gout Exacerbations". This purpose of this clinical research was to determine the efficacy and safety of an experimental drug called Rilonacept in participants with an acute gout attack. Participants participated in this study for 30 days. Rilonacept alone was being compared with Indomethacin alone and the combination of...
What is the current status of trial NCT00855920?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2009-03. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00855920?
The interventions under investigation include: Indomethacin (DRUG), Rilonacept (DRUG), Placebo (for Indomethacin) (OTHER), Placebo (for Rilonacept) (OTHER).
Who is sponsoring clinical trial NCT00855920?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.